Cargando…
Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?
Advanced glycation end products (AGE) have been implicated in diabetes associated complications. They have been suggested as potential mediators in the progression of diabetic heart failure and as a potential target for treatment. Brunvand et al. now provided evidence in that the suggested causal re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609018/ https://www.ncbi.nlm.nih.gov/pubmed/28934928 http://dx.doi.org/10.1186/s12872-017-0688-x |
_version_ | 1783265533706108928 |
---|---|
author | Schwarzer, Michael Noutsias, Michel Spillmann, Frank Schulze, P. Christian Doenst, Torsten Tschöpe, Carsten |
author_facet | Schwarzer, Michael Noutsias, Michel Spillmann, Frank Schulze, P. Christian Doenst, Torsten Tschöpe, Carsten |
author_sort | Schwarzer, Michael |
collection | PubMed |
description | Advanced glycation end products (AGE) have been implicated in diabetes associated complications. They have been suggested as potential mediators in the progression of diabetic heart failure and as a potential target for treatment. Brunvand et al. now provided evidence in that the suggested causal relationship between AGE and diastolic myocardial dysfunction cannot be confirmed in children with type 1 diabetes. The early signs of diastolic myocardial impairment were associated with higher BMI, but not with HbA1c levels. Furthermore, higher serum levels of MG-H1 and increased arterial stiffness were not significantly associated with diastolic dysfunction. The lack of association argues against an essential role of AGEs. This sobering finding does not support the potential to treat diastolic dysfunction by reduction approaches AGE in type 1 diabetic patients. Further pathogenic mechanisms involved in diabetic cardiomyopathy, such as alterations of calcium metabolism, or remodeling of the extracellular matrix, and intramyocardial inflammation may be further promising therapeutic targets. |
format | Online Article Text |
id | pubmed-5609018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56090182017-09-25 Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? Schwarzer, Michael Noutsias, Michel Spillmann, Frank Schulze, P. Christian Doenst, Torsten Tschöpe, Carsten BMC Cardiovasc Disord Correspondence Advanced glycation end products (AGE) have been implicated in diabetes associated complications. They have been suggested as potential mediators in the progression of diabetic heart failure and as a potential target for treatment. Brunvand et al. now provided evidence in that the suggested causal relationship between AGE and diastolic myocardial dysfunction cannot be confirmed in children with type 1 diabetes. The early signs of diastolic myocardial impairment were associated with higher BMI, but not with HbA1c levels. Furthermore, higher serum levels of MG-H1 and increased arterial stiffness were not significantly associated with diastolic dysfunction. The lack of association argues against an essential role of AGEs. This sobering finding does not support the potential to treat diastolic dysfunction by reduction approaches AGE in type 1 diabetic patients. Further pathogenic mechanisms involved in diabetic cardiomyopathy, such as alterations of calcium metabolism, or remodeling of the extracellular matrix, and intramyocardial inflammation may be further promising therapeutic targets. BioMed Central 2017-09-21 /pmc/articles/PMC5609018/ /pubmed/28934928 http://dx.doi.org/10.1186/s12872-017-0688-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Correspondence Schwarzer, Michael Noutsias, Michel Spillmann, Frank Schulze, P. Christian Doenst, Torsten Tschöpe, Carsten Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
title | Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
title_full | Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
title_fullStr | Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
title_full_unstemmed | Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
title_short | Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
title_sort | complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions? |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609018/ https://www.ncbi.nlm.nih.gov/pubmed/28934928 http://dx.doi.org/10.1186/s12872-017-0688-x |
work_keys_str_mv | AT schwarzermichael complexityofpathomechanismsleadingtodiastolicheartfailureindiabetesmellituspotentialfieldfortherapeuticinterventions AT noutsiasmichel complexityofpathomechanismsleadingtodiastolicheartfailureindiabetesmellituspotentialfieldfortherapeuticinterventions AT spillmannfrank complexityofpathomechanismsleadingtodiastolicheartfailureindiabetesmellituspotentialfieldfortherapeuticinterventions AT schulzepchristian complexityofpathomechanismsleadingtodiastolicheartfailureindiabetesmellituspotentialfieldfortherapeuticinterventions AT doensttorsten complexityofpathomechanismsleadingtodiastolicheartfailureindiabetesmellituspotentialfieldfortherapeuticinterventions AT tschopecarsten complexityofpathomechanismsleadingtodiastolicheartfailureindiabetesmellituspotentialfieldfortherapeuticinterventions |